Uiuce bus model

From 2013.igem.org

(Difference between revisions)
Line 435: Line 435:
                     <li><a name="data2" >Market Analysis</a></li>
                     <li><a name="data2" >Market Analysis</a></li>
                    
                    
-
                     <li><a name="data4" >Financial Plan</a></li>
+
                     <li><a name="data3" >Financial Plan</a></li>
-
                     <li><a name="data5" >Risk Analysis</a></li>
+
                     <li><a name="data4" >Risk Analysis</a></li>
             </div>
             </div>
                  
                  
Line 516: Line 516:
</div>
</div>
-
<div id="data4" style="display:none">
+
<div id="data3" style="display:none">
<center><h2>Financial Plan</h2></center><br/>
<center><h2>Financial Plan</h2></center><br/>
<p. fin plan text</p>
<p. fin plan text</p>
</div>
</div>
-
<div id="data5" style="display:none">
+
<div id="data4" style="display:none">
<center><h2>Risk Analysis</h2></center><br/>
<center><h2>Risk Analysis</h2></center><br/>
<p. risk an text</p>
<p. risk an text</p>

Revision as of 23:30, 28 October 2013

Business Model


Data

Overview


Customer Problem
The cloning process consists of several individual steps, each with its own equipment and machinery. It is complex, yet still requires a remarkable amount of human intervention. This results in errors, inconsistencies, and an overall delay in meeting significant synthetic biology milestones. Our team seeks to minimize this “human intervention” element by designing, prototyping, and commercializing an automated cloning system.



Our Solution
Our flagship product, ModuLab, is an automated system designed to optimize cloning, the underlying process of synthetic biology. The ultimate goals of ModuLab are to minimize error, maximize efficiency and provide synthetic biologists with feedback on every stage of the cloning process.